HIV reservoirs and the possibility of a cure for HIV infection

Journal of Internal Medicine

Volumn 270, Issue 6, 2011, Pages 550-560

  Palmer, S ^a,b   Josefsson, L ^a,b   Coffin, J M ^c  

^a KAROLINSKA INSTITUTE   (Sweden)

^b SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

HIV eradication; HIV latency; HIV persistence; HIV reservoirs

Indexed keywords

CD4+ T LYMPHOCYTE; CELL DIVISION; CELL PROLIFERATION; CONFERENCE PAPER; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEMORY T LYMPHOCYTE; PRIORITY JOURNAL; VIREMIA;

ANTI-HIV AGENTS; CD4-POSITIVE T-LYMPHOCYTES; DISEASE RESERVOIRS; HIV INFECTIONS; HIV-1; HUMANS; VIREMIA; VIRUS LATENCY;

EID: 81855218589     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2011.02457.x     Document Type: Conference Paper

References (96)

1. Havlir DV et al. Prevalence and predictive value of intermittent viremia with combination HIV therapy. JAMA 2001; 286: 171-9.
2. Havlir DV et al. Predictors of residual viremia in HIV-infected patients successfully treated with efavirenz and lamivudine plus either tenofovir or stavudine. J Infect Dis 2005; 191: 1164-8.
3. Maldarelli F et al. ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia. PLoS Pathog 2007; 3: e46.
4. Palmer S et al. New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol 2003; 41: 4531-6.
5. Palmer S et al. Low-level viremia persists for at least 7years in patients on suppressive antiretroviral therapy. Proc Natl Acad Sci U S A 2008; 105: 3879-84.
6. Davey Jr RT et al. HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. Proc Natl Acad Sci U S A 1999; 96: 15109-14.
7. Dornadula G et al. Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. JAMA 1999; 282: 1627-32.
8. Lewin SR et al. Use of real-time PCR and molecular beacons to detect virus replication in human immunodeficiency virus type 1-infected individuals on prolonged effective antiretroviral therapy. J Virol 1999; 73: 6099-103.
9. Zhang L et al. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N Engl J Med 1999; 340: 1605-13.
10. Coffin JM. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 1995; 267: 483-9.
11. Perelson AS et al. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 1997; 387: 188-91.
12. Havlir DV et al. Productive infection maintains a dynamic steady state of residual viremia in human immunodeficiency virus type 1-infected persons treated with suppressive antiretroviral therapy for five years. J Virol 2003; 77: 11212-9.
13. Ramratnam B et al. Intensification of antiretroviral therapy accelerates the decay of the HIV-1 latent reservoir and decreases, but does not eliminate, ongoing virus replication. J Acquir Immune Defic Syndr 2004; 35: 33-7.
14. Dinoso JB et al. Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy. Proc Natl Acad Sci U S A 2009; 106: 9403-8.
15. Gandhi RT et al. The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial. PLoS Med 2010; 7: 1-11.
16. Hatano H et al. A randomized, controlled trial of raltegravir intensification in antiretroviral-treated, HIV-infected patients with a suboptimal CD4+ T cell response. J Infect Dis 2011; 203: 960-8.
17. McMahon D et al. Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy. Clin Infect Dis 2010; 50: 912-9.
18. Bailey JR et al. Residual human immunodeficiency virus type 1 viremia in some patients on antiretroviral therapy is dominated by a small number of invariant clones rarely found in circulating CD4+ T cells. J Virol 2006; 80: 6441-57.
19. Joos B et al. HIV rebounds from latently infected cells, rather than from continuing low-level replication. Proc Natl Acad Sci U S A 2008; 105: 16725-30.
20. Buzon MJ et al. HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. Nat Med 2010; 16: 460-5.
21. Yukl SA et al. Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy. AIDS 2010; 24: 2451-60.
22. Ho DD et al. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995; 373: 123-6.
23. Wei X et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995; 373: 117-22.
24. Ho DD, Rota TR, Hirsch MS. Infection of monocyte/macrophages by human T-lymphotrophic virus type III. J Clin Invest 1986; 77: 1712-5.
25. Nicholson JK et al. In vitro infection of human monocytes with human T lymphotropic virus type III/lymphadenopathyassociated virus (HTLV-III/LAV). J Immunol 1986; 137: 323-9.
26. Popov S et al. Long-term productive human immunodeficiency virus infection of CD1a-sorted myeloid dendritic cells. J Virol 2005; 79: 602-8.
27. Kalter DC, Gendelman HE, Meltzer MS. Monocytes, dendritic cells, and Langerhans cells in human immunodeficiency virus infection. Dermatol Clin 1991; 9: 415-28.
28. Kalter DC et al. Epidermal Langerhans cells are not principal reservoirs of virus in HIV disease. J Immunol 1991; 146: 3396-404.
29. Pugh CW, MacPherson GG, Steer HW. Characterization of nonlymphoid cells derived from rat peripheral lymph. J Exp Med 1983; 157: 1758-79.
30. Otero M et al. Peripheral blood dendritic cells are not a major reservoir for HIV type 1 in infected individuals on virally suppressive HAART. AIDS Res Hum Retroviruses 2003; 19: 1097-103.
31. Smith BA et al. Persistence of infectious HIV on follicular dendritic cells. J Immunol 2001; 166: 690-6.
32. Murray JM et al. Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase. AIDS 2007; 21: 2315-21.
33. Spivak AM et al. Dynamic constraints on the second phase compartment of HIV-infected cells. AIDS Res Hum Retroviruses 2011; 27: 759-61.
34. Chun TW et al. Induction of HIV-1 replication in latently infected CD4+ T cells using a combination of cytokines. J Exp Med 1998; 188: 83-91.
35. Prins JM et al. Immuno-activation with anti-CD3 and recombinant human IL-2 in HIV-1-infected patients on potent antiretroviral therapy. AIDS 1999; 13: 2405-10.
36. Siliciano JD et al. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med 2003; 9: 727-8.
37. Chun TW et al. Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection. Proc Natl Acad Sci U S A 1998; 95: 8869-73.
38. Chun TW et al. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci U S A 1997; 94: 13193-7.
39. Chomont N et al. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med 2009; 15: 893-900.
40. Brennan TP et al. Analysis of human immunodeficiency virus type 1 viremia and provirus in resting CD4+ T cells reveals a novel source of residual viremia in patients on antiretroviral therapy. J Virol 2009; 83: 8470-81.
41. Gunthard HF et al. Residual human immunodeficiency virus (HIV) Type 1 RNA and DNA in lymph nodes and HIV RNA in genital secretions and in cerebrospinal fluid after suppression of viremia for 2years. J Infect Dis 2001; 183: 1318-27.
42. Pantaleo G, Graziosi C, Fauci AS. New concepts in the immunopathogenesis of human immunodeficiency virus infection. N Engl J Med 1993; 328: 327-35.
43. Veazey RS et al. Gastrointestinal tract as a major site of CD4+ T cell depletion and viral replication in SIV infection. Science 1998; 280: 427-31.
44. Veazey RS, Lackner AA. The gastrointestinal tract and the pathogenesis of AIDS. AIDS 1998; 12(Suppl A): S35-42.
45. Guadalupe M et al. Viral suppression and immune restoration in the gastrointestinal mucosa of human immunodeficiency virus type 1-infected patients initiating therapy during primary or chronic infection. J Virol 2006; 80: 8236-47.
46. Gisslen M et al. Cerebrospinal fluid viral load, intrathecal immunoactivation, and cerebrospinal fluid monocytic cell count in HIV-1 infection. J Acquir Immune Defic Syndr 1999; 21: 271-6.
47. Hagberg L et al. Kinetics of HIV-1 in cerebrospinal fluid and serum after zidovudine treatment. J Neuro AIDS 1999; 2: 29-35.
48. Kaul M. HIV-1 associated dementia: update on pathological mechanisms and therapeutic approaches. Curr Opin Neurol 2009; 22: 315-20.
49. Strain MC et al. Effect of treatment, during primary infection, on establishment and clearance of cellular reservoirs of HIV-1. J Infect Dis 2005; 191: 1410-8.
50. Wong JK et al. In vivo compartmentalization of human immunodeficiency virus: evidence from the examination of pol sequences from autopsy tissues. J Virol 1997; 71: 2059-71.
51. Aquaro S et al. HIV-1-associated dementia during HAART therapy. Recent Pat CNS Drug Discov 2008; 3: 23-33.
52. Price RW, Spudich S. Antiretroviral therapy and central nervous system HIV type 1 infection. J Infect Dis 2008; 197(Suppl 3): S294-306.
53. Varatharajan L, Thomas SA. The transport of anti-HIV drugs across blood-CNS interfaces: summary of current knowledge and recommendations for further research. Antiviral Res 2009; 84: A99-109.
54. Yilmaz A et al. Treatment intensification has no effect on the HIV-1 central nervous system infection in patients on suppressive antiretroviral therapy. J Acquir Immune Defic Syndr 2010; 55: 590-6.
55. Kiessling AA et al. Human immunodeficiency virus in semen arises from a genetically distinct virus reservoir. AIDS Res Hum Retroviruses 1998; 14(Suppl 1): S33-41.
56. Vernazza PL et al. Detection and biologic characterization of infectious HIV-1 in semen of seropositive men. AIDS 1994; 8: 1325-9.
57. Zhang H et al. Human immunodeficiency virus type 1 in the semen of men receiving highly active antiretroviral therapy. N Engl J Med 1998; 339: 1803-9.
58. Bruggeman LA et al. Renal epithelium is a previously unrecognized site of HIV-1 infection. J Am Soc Nephrol 2000; 11: 2079-87.
59. Chun TW et al. In vivo fate of HIV-1-infected T cells: quantitative analysis of the transition to stable latency. Nat Med 1995; 1: 1284-90.
60. Bednarik DP, Mosca JD, Raj NB. Methylation as a modulator of expression of human immunodeficiency virus. J Virol 1987; 61: 1253-7.
61. Ylisastigui L et al. Coaxing HIV-1 from resting CD4 T cells: histone deacetylase inhibition allows latent viral expression. AIDS 2004; 18: 1101-8.
62. Kauder SE et al. Epigenetic regulation of HIV-1 latency by cytosine methylation. PLoS Pathog 2009; 5: e1000495.
63. Dahl V, Josefsson L, Palmer S. HIV reservoirs, latency, and reactivation: prospects for eradication. Antiviral Res 2010; 85: 286-94.
64. Han Y et al. Resting CD4+ T cells from human immunodeficiency virus type 1 (HIV-1)-infected individuals carry integrated HIV-1 genomes within actively transcribed host genes. J Virol 2004; 78: 6122-33.
65. Jordan A, Bisgrove D, Verdin E. HIV reproducibly establishes a latent infection after acute infection of T cells in vitro. EMBO J 2003; 22: 1868-77.
66. Lenasi T, Contreras X, Peterlin BM. Transcriptional interference antagonizes proviral gene expression to promote HIV latency. Cell Host Microbe 2008; 4: 123-33.
67. Archin NM et al. Expression of latent human immunodeficiency type 1 is induced by novel and selective histone deacetylase inhibitors. AIDS 2009; 23: 1799-806.
68. Pomerantz RJ et al. Cells nonproductively infected with HIV-1 exhibit an aberrant pattern of viral RNA expression: a molecular model for latency. Cell 1990; 61: 1271-6.
69. Blazkova J et al. CpG methylation controls reactivation of HIV from latency. PLoS Pathog 2009; 5: e1000554.
70. Bosque A, Planelles V. Induction of HIV-1 latency and reactivation in primary memory CD4+ T cells. Blood 2009; 113: 58-65.
71. Tyagi M, Pearson RJ, Karn J. Establishment of HIV latency in primary CD4+ cells is due to epigenetic transcriptional silencing and P-TEFb restriction. J Virol 2010; 84: 6425-37.
72. Yang HC et al. Small-molecule screening using a human primary cell model of HIV latency identifies compounds that reverse latency without cellular activation. J Clin Invest 2009; 119: 3473-86.
73. Brady T et al. HIV integration site distributions in resting and activated CD4+ T cells infected in culture. AIDS 2009; 23: 1461-71.
74. Crowe S, Zhu T, Muller WA. The contribution of monocyte infection and trafficking to viral persistence, and maintenance of the viral reservoir in HIV infection. J Leukoc Biol 2003; 74: 635-41.
75. Crowe SM, Sonza S. HIV-1 can be recovered from a variety of cells including peripheral blood monocytes of patients receiving highly active antiretroviral therapy: a further obstacle to eradication. J Leukoc Biol 2000; 68: 345-50.
76. Levy Y et al. Enhanced T cell recovery in HIV-1-infected adults through IL-7 treatment. J Clin Invest 2009; 119: 997-1007.
77. Scripture-Adams DD et al. Interleukin-7 induces expression of latent human immunodeficiency virus type 1 with minimal effects on T-cell phenotype. J Virol 2002; 76: 13077-82.
78. Sereti I et al. IL-7 administration drives T cell-cycle entry and expansion in HIV-1 infection. Blood 2009; 113: 6304-14.
79. Wang FX et al. IL-7 is a potent and proviral strain-specific inducer of latent HIV-1 cellular reservoirs of infected individuals on virally suppressive HAART. J Clin Invest 2005; 115: 128-37.
80. Lehrman G et al. Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet 2005; 366: 549-55.
81. Siliciano JD et al. Stability of the latent reservoir for HIV-1 in patients receiving valproic acid. J Infect Dis 2007; 195: 833-6.
82. Reuse S et al. Synergistic activation of HIV-1 expression by deacetylase inhibitors and prostratin: implications for treatment of latent infection. PLoS ONE 2009; 4: e6093.
83. Burnett JC et al. Combinatorial latency reactivation for HIV-1 subtypes and variants. J Virol 2010; 84: 5958-74.
84. Archin NM et al. Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid. AIDS Res Hum Retroviruses 2009; 25: 207-12.
85. Contreras X et al. Suberoylanilide hydroxamic acid reactivates HIV from latently infected cells. J Biol Chem 2009; 284: 6782-9.
86. Jones J et al. High throughput drug screening for human immunodeficiency virus type 1 reactivating compounds. Assay Drug Dev Technol 2007; 5: 181-9.
87. Yang HC et al. Isolation of a cellular factor that can reactivate latent HIV-1 without T cell activation. Proc Natl Acad Sci U S A 2009; 106: 6321-6.
88. Wolschendorf F et al. Hit-and-run stimulation: a novel concept to reactivate latent HIV-1 infection without cytokine gene induction. J Virol 2010; 84: 8712-20.
89. Dinoso JB et al. A simian immunodeficiency virus-infected macaque model to study viral reservoirs that persist during highly active antiretroviral therapy. J Virol 2009; 83: 9247-57.
90. North TW et al. Viral sanctuaries during highly active antiretroviral therapy in a nonhuman primate model for AIDS. J Virol 2010; 84: 2913-22.
91. Sun Z et al. Intrarectal transmission, systemic infection, and CD4+ T cell depletion in humanized mice infected with HIV-1. J Exp Med 2007; 204: 705-14.
92. Lindkvist A et al. Reduction of the HIV-1 reservoir in resting CD4+ T-lymphocytes by high dosage intravenous immunoglobulin treatment: a proof-of-concept study. AIDS Res Ther 2009; 6: 15.
93. Negi VS et al. Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J Clin Immunol 2007; 27: 233-45.
94. Hutter G et al. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med 2009; 360: 692-8.
95. Holt N et al. Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo. Nat Biotechnol 2010; 28: 839-47.
96. Perez EE et al. Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases. Nat Biotechnol 2008; 26: 808-16.